Agency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Collection of Data Relating to the Prevention of Medical Gas Mixups at Health Care Facilities-Survey, 122-123 [E5-8113]
Download as PDF
122
Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices
by NIOSH. All comments in the NORA
Docket will be used to help shape
sector-specific and related cross-sector
research agendas for the nation.
These events are part of a series of
public meetings which will occur in the
months preceding the NORA
Symposium (April 18–20, 2006 in
Washington, DC). Upcoming meetings
will include: Wholesale and Retail
Trade; Manufacturing; Mining; Services;
Regional Issues; and a summary session.
Future Federal Register announcements
will provide more information on these
meetings. Previous meetings have
discussed Transportation, Warehousing,
and Utilities, and Construction.
Contact Person for More Information:
Sid Soderholm, Ph.D., NORA
Coordinator, (202) 401–0721.
Address: Comments may also be emailed to niocindocket@cdc.gov, or sent
via postal mail to: Docket NIOSH–047,
Robert A. Taft Laboratories (C–34), 4676
Columbia Parkway, Cincinnati, OH
45226.
Stakeholders are also invited to
submit comments electronically at the
NORA Web page https://www.cdc.gov/
niosh/nora. Comments submitted to the
Web page by others can also be viewed
there.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: December 27, 2005.
B. Kathy Skipper,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E5–8192 Filed 12–30–05; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
rmajette on DSK29S0YB1PROD with NOTICES6
[Docket No. 2005N–0500]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Requirements for
Collection of Data Relating to the
Prevention of Medical Gas Mixups at
Health Care Facilities—Survey
AGENCY:
Food and Drug Administration,
HHS.
VerDate Mar<15>2010
15:46 Nov 10, 2010
Jkt 223001
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
measures, taken by certain health care
medical facilities that use medical
oxygen, to prevent mixups with other
gases.
DATES: Submit written or electronic
comments on the collection of
information by March 6, 2006.
ADDRESSES: Submit electronic
comments on the collection of
information to https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane,
room 1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Karen Nelson, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1482.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Requirements for Collection of Data
Relating to the Prevention of Medical
Gas Mixups at Health Care Facilities—
Survey (OMB Control Number 0910–
0548)—Extension
FDA has received four reports of
medical gas mixups occurring during
the past 7 years. These reports were
received from hospitals and nursing
homes and involved 7 deaths and 15
injuries to patients who were thought to
be receiving medical grade oxygen, but
who were actually receiving a different
gas (e.g., nitrogen, argon) that had been
mistakenly connected to the facility’s
oxygen supply system. In 2001, FDA
published guidance making
recommendations to help hospitals,
nursing homes, and other health care
facilities avoid the tragedies that result
from medical gas mixups and alerting
these facilities to the hazards. This
survey is intended to assess the degree
of facilities’ compliance with safety
measures to prevent mixups and to
determine if further steps are warranted
to ensure the safety of patients.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\03JAN1.SGM
03JAN1
123
Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
210 and 211
Annual Frequency
per Response
285
Total Annual
Responses
1
Hours per
Response
285
Total Hours
.25
Total
71.25
71.25
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
OMB control number 0910–0116. The
approval expires on December 31, 2008.
A copy of the supporting statement for
this information collection is available
on the Internet at https://www.fda.gov/
ohrms/dockets.
ADDRESSES: Comments may be
submitted electronically at the TRWG
Web site: https://www.cancer.gov/trwg/.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
Food and Drug Administration
[FR Doc. E5–8134 Filed 12–30–05; 8:45 am]
The National Cancer Institute is
committed to speeding the development
of new diagnostic tests, cancer
treatments, and other interventions that
benefit people with cancer and people
at risk for cancer. Such development
relies on strong translational research
collaborations between basic and
clinical scientists to generate novel
approaches. Currently, NCI supports a
variety of projects that build this bridge
between basic science and patient care.
Over the next year, the Translational
Research Working Group (TRWG) will
review NCI’s current intramural and
extramural translational research
portfolio (within the scope of the TRWG
mission), facilitate broad community
input, invite public comment, and
recommend ways to improve and
integrate efforts. The ultimate goal is to
accelerate progress toward improving
the health of the nation and cancer
patient outcomes.
[FR Doc. E5–8113 Filed 12–30–05; 8:45 am]
BILLING CODE 4160–01–S
BILLING CODE 4160–01–S
[Docket No. 2005N–0220]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Current Good Manufacturing Practices
and Related Regulations for Blood and
Blood Components; and Requirements
for Donor Testing, Donor Notification,
and ‘‘Lookback’’
AGENCY:
Food and Drug Administration,
HHS.
rmajette on DSK29S0YB1PROD with NOTICES6
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Current Good Manufacturing Practices
and Related Regulations for Blood and
Blood Components; and Requirements
for Donor Testing, Donor Notification,
and ‘Lookback’’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 24, 2005 (70
FR 61447), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
VerDate Mar<15>2010
15:46 Nov 10, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Health
Translational Research Working Group
Public Comment Period
AGENCY: National Cancer Institute (NCI),
National Institutes of Health (NIH),
Department of Health and Human
Services (DHHS).
ACTION: Request for public comment.
SUMMARY: The Translational Research
Working Group (TRWG), a broad panel
including advocates, researchers from
academia, industry representatives, and
government officials, was established in
early 2005 to evaluate the status of the
National Cancer Institute’s (NCI)
intramural and extramural investment
in translational research in order to
develop recommendations on ways to
coordinate and optimally integrate
activities. The TRWG is also charged
with developing implementation
strategies that will enable the scientific
community and NCI leadership to
appropriately prioritize its translational
research opportunities.
Recommendations will be made to the
National Cancer Advisory Board by
early 2007. To assist in its future
planning efforts, TRWG is asking public
stakeholders in the translational
research enterprise for feedback on
some of the key questions facing the
panel and insights on how to proceed.
DATES: The TRWG public comment
period will run from December 20, 2005
to January 20, 2006.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Background
Request for Comments
To better understand the different
viewpoints in the cancer research
community, and to develop and reflect
a common understanding about the
challenges and opportunities in
translational research, TRWG seeks
input on six important areas:
• Barriers to/Incentives for
Translational Research.
• Prioritization.
• Funding.
• System Organization.
• Facilities/Technologies.
• Manpower/Training.
Dated: December 22, 2005.
Ernest Hawk,
Director, Office of Centers, Training and
Resources, National Cancer Institute,
National Institutes of Health.
[FR Doc. 05–24687 Filed 12–30–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\03JAN1.SGM
03JAN1
Agencies
[Federal Register Volume 71, Number 1 (Tuesday, January 3, 2006)]
[Notices]
[Pages 122-123]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0500]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Requirements for Collection of Data Relating to the
Prevention of Medical Gas Mixups at Health Care Facilities--Survey
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on measures, taken by certain
health care medical facilities that use medical oxygen, to prevent
mixups with other gases.
DATES: Submit written or electronic comments on the collection of
information by March 6, 2006.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.fda.gov/dockets/ecomments. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, room 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Karen Nelson, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Requirements for Collection of Data Relating to the Prevention of
Medical Gas Mixups at Health Care Facilities--Survey (OMB Control
Number 0910-0548)--Extension
FDA has received four reports of medical gas mixups occurring
during the past 7 years. These reports were received from hospitals and
nursing homes and involved 7 deaths and 15 injuries to patients who
were thought to be receiving medical grade oxygen, but who were
actually receiving a different gas (e.g., nitrogen, argon) that had
been mistakenly connected to the facility's oxygen supply system. In
2001, FDA published guidance making recommendations to help hospitals,
nursing homes, and other health care facilities avoid the tragedies
that result from medical gas mixups and alerting these facilities to
the hazards. This survey is intended to assess the degree of
facilities' compliance with safety measures to prevent mixups and to
determine if further steps are warranted to ensure the safety of
patients.
FDA estimates the burden of this collection of information as
follows:
[[Page 123]]
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
210 and 211 285 1 285 .25 71.25
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 71.25
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5-8113 Filed 12-30-05; 8:45 am]
BILLING CODE 4160-01-S